Protocol 2: Intermediate approach (experienced researchers) Goal: Multi-target immune modulation with anti-inflammatory support Components: Thymosin alpha-1: 1.6 mg subcutaneously, three times weekly KPV: 200-500 mcg subcutaneously, once daily BPC-157: 250 mcg subcutaneously, twice daily Selank: 250-500 mcg intranasally, once daily Schedule: Monday, Wednesday, Friday: Thymosin alpha-1 Daily AM: KPV + BPC-157 Daily PM: BPC-157 Daily: Selank nasal spray (morning or midday) Duration: 12 weeks on, 4 weeks off Monitoring: Baseline labs, repeat every 4 weeks
2017 National Population Projections Tables
Emerging research has shed light on the potential involvement of TB-500 in the pathogenesis of rheumatoid arthritis (RA)
Groneberg D, Springer J, Fischer A
10.1590/0100-3984.2020.53.1e2 218 ShantoP
This resin works well with small and large proteins tagged with GST in batch or column purifications (Low Flow)